Catheter having window and partial balloon covering for dissecting tissue planes and injecting treatment agent to coronary blood vessel

Patent metadata

Field	Value
Publication number	US-9504491-B2
Application number	US-93666807-A
Country	US
Kind code	B2
Filing date	Nov 7, 2007
Priority date	Nov 7, 2007
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

A method is provided including introducing a delivery device through a vessel wall to a treatment site within one of a peri-adventitial space or a pericardium adjacent a coronary blood vessel and delivering a treatment agent through the delivery device. The treatment agent is delivered through the delivery device according to conditions that hydraulically dissect tissue planes within the peri-adventitial space. A kit is provided including a delivery device having a needle to be advanced through one of an epicardium of a heart and a wall of a coronary blood vessel into a peri-adventitial space and a treatment agent comprising particles having an average diameter on the order of 15 microns or more to be delivered through the delivery device into the peri-adventitial space.

First claim

What is claimed is:

1. A method comprising:
advancing a catheter assembly within a lumen of a coronary blood vessel, the catheter assembly having a primary cannula attached at a distal end to a cylindrical housing, the cylindrical housing having a window formed through one side and a balloon formed around another side of the cylindrical housing, wherein the balloon extends around less than an entire circumference of the cylindrical housing and wherein the balloon is positioned between an outer surface of the cylindrical housing and a vessel wall of the coronary blood vessel such that when the balloon is inflated the balloon contacts a portion of the vessel wall adjacent the balloon and moves the one side of the cylindrical housing toward a portion of the vessel wall adjacent the window to press the window against the vessel wall;
introducing a needle through the window to the vessel wall and into a treatment site within one of a peri-adventitial space or a pericardium adjacent the coronary blood vessel by advancing the needle through the window;
delivering a first substance through the needle and out an end of the needle directly to the treatment site at a pressure sufficient to hydraulically dissect tissue planes within the peri-adventitial space or the pericardium adjacent the coronary blood vessel, wherein the first substance is delivered in an amount of at least 1.0 cc and the pressure sufficient to hydraulically dissect tissue planes is from about 30 mm Hg to about 150 mm Hg;
withdrawing the first substance through the needle once the tissue planes are dissected; and
delivering a second substance comprising a treatment agent through the needle and into the dissected tissue planes, and wherein an amount of the second substance is less than the amount of the first substance.

2. The method of claim 1 wherein at least 0.1 cc of the treatment agent is delivered through the needle.

3. The method of claim 1 wherein the needle is capable of one of subxyphoid, sub-sternal and thoracascopic access to the treatment site.

4. The method of claim 1 wherein between 0.1 cc and 20 cc of the treatment agent is introduced to the peri-adventitial space.

5. The method of claim 1 wherein the treatment agent is a drug selected from a group consisting of an HDL mimetic, an anti-inflammatory and an anti-proliferative.

6. The method of claim 1 wherein the treatment agent is a non-living biologic selected from a group consisting of extra cellular matrix, urinary bladder matrix, small intestinal submucosa and liver derived biomatrix.

7. The method of claim 1 wherein the treatment agent is a living biologic selected from a group consisting of bone marrow stem cells, mesenchymal cells and endothelial progenitor cells.

8. The method of claim 7 wherein the living biologic is composed of a mixture of a matrix gel and drug loaded particles.

9. The method of claim 1 wherein the treatment agent is composed of one of a nanoparticle and a microparticle.

10. The method of claim 9 wherein the one of the nanoparticle and the microparticle have an average diameter of about 15 microns or more.

11. The method of claim 1 wherein the treatment agent is composed of a gel.

Assignees

• Callas Peter L
• Willis Eric J
• El-Nounou Fozan O
• Ludwig Florian N
• Webler William E
• Consigny Paul M
• Abbott Cardiovascular Systems Inc

Inventors

• Callas Peter L
• Willis Eric J
• El-Nounou Fozan O
• Ludwig Florian N
• Webler William E
• Consigny Paul M

Classifications

• A61B2017/00247

  Making holes in the wall of the heart, e.g. laser Myocardial revascularization · CPC title

• A61M25/0026

  Multi-lumen catheters with stationary elements (catheter assemblies comprising a catheter in combination with a guide tube, sheath or sleeve A61M2025/0681; catheters comprising telescoping coaxial elements A61M2025/0175) · CPC title

• A61B2018/00392

  Transmyocardial revascularisation · CPC title

• A61B17/02

  for holding wounds open, e.g. retractors; Tractors · CPC title

• A61M2025/0166

  Sensors, electrodes or the like for guiding the catheter to a target zone, e.g. image guided or magnetically guided · CPC title